再評価される丸山ワクチンは223Ra内用療法の治療成績を向上させる併用薬となりうるか?

Research Project

Project/Area Number	23K07120
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 52040:Radiological sciences-related
Research Institution	Kawasaki Medical School
Principal Investigator	犬伏正幸川崎医科大学, 医学部, 准教授 (70399830)
Co-Investigator(Kenkyū-buntansha)	宮地禎幸川崎医科大学, 医学部, 教授 (00294463)
Project Period (FY)	2023-04-01 – 2028-03-31
Project Status	Granted (Fiscal Year 2023)
Budget Amount *help	¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2027: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2026: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000) Fiscal Year 2025: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000) Fiscal Year 2024: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000) Fiscal Year 2023: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Keywords	RI内用療法
Outline of Research at the Start	丸山ワクチン(アンサー)併用223Ra内用療法を今後5年間で約20例実施し、非併用の自施設過去症例(6年間で23例)と比較して6回投与完遂率や予後(SSE,OS)が改善するかを検証する。